- Home
- SKYE vs FLL Comparison
SKYE vs FLL Comparison
Compare SKYE & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | FLL |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 90.3M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | SKYE | FLL |
|---|---|---|
| Price | $0.87 | $2.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $14.75 | $5.00 |
| AVG Volume (30 Days) | ★ 494.0K | 193.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $299,916,000.00 |
| Revenue This Year | N/A | $4.87 |
| Revenue Next Year | N/A | $7.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $0.68 | $2.25 |
| 52 Week High | $5.75 | $5.59 |
Technical Indicators
Market Signals| Indicator | SKYE | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 40.63 |
| Support Level | $0.68 | $2.59 |
| Resistance Level | $0.95 | $2.71 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 38.81 | 2.74 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.